This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Shopify (SHOP) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
Shopify's (SHOP) third-quarter results are likely to benefit from focus on developing merchant base, addition of new functionalities, robust partner ecosystem and solid mobile domain.
Merck (MRK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to drive third-quarter sales. However, genericization of key drugs and increasing competition are concerns.
Is a Beat in Store for Bristol-Myers (BMY) in Q3 Earnings?
by Zacks Equity Research
Bristol-Myers (BMY) is scheduled to report third-quarter earnings on Oct 25.
New Strong Buy Stocks for October 22nd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
BMY vs. LLY: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
BMY vs. LLY: Which Stock Is the Better Value Option?
ServiceNow (NOW) to Report Q3 Earnings: Is a Beat in Store?
by Zacks Equity Research
ServiceNow's (NOW) third-quarter 2018 results are expected to benefit from growing G2K customer base and rapid penetration in non-ITSM markets.
Is a Beat in Store for Citrix Systems (CTXS) in Q3 Earnings?
by Zacks Equity Research
Citrix's (CTXS) third-quarter results are expected to benefit from impressive growth in subscription-based services segment and buyout synergies.
Factors Setting the Tone for AspenTech (AZPN) in Q1 Earnings
by Zacks Equity Research
Aspen Technolgy's (AZPN) first-quarter results are expected to benefit from growth in APM pipeline. However, reduced capital expenditure in the energy vertical remains a concern.
Bristol-Myers Squibb (BMY) Q3 Earnings Preview: How Are Events Shaping Up?
by Zacks Equity Research
Bristol-Myers (BMY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck's Keytruda on a Roll in a Thriving Anti-PD-L1 Market
by Zacks Equity Research
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
J&J (JNJ) Beats Earnings & Sales Estimates in Q3, Ups View
by Zacks Equity Research
J&J (JNJ) beats estimates for both earnings and sales in the third quarter of 2018 and raises full-year forecast.
Bristol-Myers Reports Disappointing Data From SCLC Study
by Zacks Equity Research
Bristol-Myers??? (BMY) late-stage study on blockbuster immuno-oncology drug, Opdivo for the treatment of SCLC fails.
Zacks.com highlights: Bristol-Myers Squibb, Celanese, Ternium S.A. and Mettler-Toledo International
by Zacks Equity Research
Zacks.com highlights: Bristol-Myers Squibb, Celanese, Ternium S.A. and Mettler-Toledo International
New Strong Buy Stocks for October 15th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday
Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal
by Zacks Equity Research
AbbVie (ABBV) signs licensing deal with Sandoz, the generic arm of Novartis. J&J (JNJ) gains FDA approval for label expansion of its blood thinner, Xarelto.
Bristol-Myers Inks Deal and Invests $12 Million in Compugen
by Zacks Equity Research
Bristol-Myers (BMY) enters a clinical trial collaboration with Compugen and will make a $12-million equity investment in the latter.
4 Top Stocks to Buy for Superb Earnings Growth
by Tirthankar Chakraborty
We select four stocks that have striking earnings growth and positive estimate revisions.
Novartis Presents Positive Data on Sickle Cell Disease Drug
by Zacks Equity Research
Novartis (NVS) announces positive results from a post hoc analysis of the phase II study, SUSTAIN, on pipeline candidate, crizanlizumab, being published in the American Journal of Hematology.
3 Reasons Momentum Stock Investors Will Love Bristol-Myers Squibb (BMY)
by Zacks Equity Research
Bristol-Myers Squibb (BMY) stock is looking quite impressive for momentum-oriented investors as it has favorable price performance and is also seeing positive estimate revisions.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH
AbbVie's Orilissa Gets Canadian Nod to Treat Endometriosis
by Zacks Equity Research
AbbVie (ABBV) and Neurocrine receive Canadian approval for Orilissa, for the treatment of moderate to severe pain associated with endometriosis.
The Zacks Analyst Blog Highlights: Home Depot, Bristol-Myers, Costco, Ecolab and Ameriprise Financial
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, Bristol-Myers, Costco, Ecolab and Ameriprise Financial
Why Bristol-Myers Squibb (BMY) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Bristol-Myers Squibb (BMY) have what it takes? Let's find out.
Merck Reports Positive Efficacy Data from Phase III HIV Study
by Zacks Equity Research
Merck (MRK) reports positive data from the phase III DRIVE-AHEAD study, evaluating Delstrigo in treatment-naive adults with HIV-1 infection.
Top Analyst Reports for Home Depot, Bristol-Myers & Costco
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Home Depot (HD), Bristol-Myers (BMY) and Costco (COST).